Figure 2From: Phase I dose escalation pharmacokinetic assessment of intravenous humanized anti-MUC1 antibody AS1402 in patients with advanced breast cancerAS1402 Cmax (a) and AS1402 AUC0-∞ (b) versus dose proportionality in patients receiving doses of 1 mg/kg (circle), 3 mg/kg (triangle), 9 mg/kg (square), or 16 mg/kg (triangle).Back to article page